FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3032544449> ?p ?o ?g. }

• W3032544449 endingPage "10005" @default.
• W3032544449 startingPage "10005" @default.
• W3032544449 abstract "10005 Background: PD1 induces long-term responses in approximately 30% of MM pts, however 2/3 are resistant (innate or acquired) and will require further treatment. A subset of these pts will benefit from IPI or IPI+PD1, but these pts are yet to be identified. We sought to determine; i) response rate (RR) and survival to IPI+/-PD1 after PD1 progression, and ii) clinical predictors of response and survival to IPI+/-PD1. Methods: MM pts resistant to PD1 and then treated with IPI+/-PD1 were studied. Demographics, disease characteristics and baseline blood parameters were examined. Univariate, multivariate and backward elimination technique analyses were performed to create predictive models of response and overall survival (OS). Results: Of 330 MM pts resistant to PD1 (median time to prog 2.9 months [0.5 – 42.3], 12% adjuvant, 88% metastatic; 70% innate, 30% acquired), 161 (49%) had subsequent IPI and 169 (51%) had IPI+PD1. Characteristics at start of IPI+/-PD1 were similar in IPI vs IPI+PD1 groups (stage M1D 27% vs 34%; elevated LDH 38% vs 40%), except IPI group had more ECOG ≥1 (60% vs 34%) and less BRAF mutation (mut) (21% vs 37%). Median follow-up from start of IPI+/-PD1 was 22.3 months (19.8 - 25.8); RR was 22%, higher in IPI+PD1 (31%) vs IPI (12%) (p < 0.01). PFS and OS at 1 year were 20% and 48%, respectively; better with IPI+PD1 (27%/57%) vs IPI (13%/38%) (p < 0.01). PD1 setting (adjuvant/metastatic) and response did not impact response to IPI+/-PD1. Most pts progressing on adjuvant PD1 had IPI+PD1 (88%) and RR was 33%. Neither the interval between PD1 and IPI+/-PD1 nor use of other drugs affected response to IPI+/-PD1. RR was similar in BRAF WT (23%) vs BRAF mut (RR 21%) pts. In BRAF WT pts, RR was higher with IPI+PD1 vs IPI (38% vs 9%, p < 0.01), while RR was similar with IPI (24%) or IPI+PD1 (19%) in BRAF mut pts. One third of BRAF mut pts had BRAF inhibitors (BRAFi) prior to IPI+/-PD1 and lower RR (13%) vs those without BRAFi (RR = 25%, p > 0.05). High grade (≥G3) toxicity (tox) was similar with IPI+PD1 (30%) or IPI (34%, p = 0.48), and was not associated with response. Stage III/M1A/M1B, normal LDH and treatment with IPI+PD1 were the best predictors of response (AUC = 0.69). These factors, in addition to sex (male), ECOG PS = 0, BRAF mut, progressed/recurred > 3 months on PD1, and absence of bone mets were the best predictors of longer OS (AUC = 0.74). Conclusions: In pts resistant to PD1, IPI+PD1 has higher RR, longer survival, yet similar high grade tox than IPI alone. Predictive models of response & survival will help select pts for IPI+/-PD1 after progressing on PD1." @default.
• W3032544449 created "2020-06-05" @default.
• W3032544449 creator A5003153310 @default.
• W3032544449 creator A5013399740 @default.
• W3032544449 creator A5022520811 @default.
• W3032544449 creator A5022668182 @default.
• W3032544449 creator A5025478490 @default.
• W3032544449 creator A5029398339 @default.
• W3032544449 creator A5036987287 @default.
• W3032544449 creator A5038759671 @default.
• W3032544449 creator A5040969461 @default.
• W3032544449 creator A5050031536 @default.
• W3032544449 creator A5052403208 @default.
• W3032544449 creator A5059961435 @default.
• W3032544449 creator A5064923908 @default.
• W3032544449 creator A5069983533 @default.
• W3032544449 creator A5070576000 @default.
• W3032544449 creator A5071144743 @default.
• W3032544449 creator A5082278497 @default.
• W3032544449 creator A5087156406 @default.
• W3032544449 creator A5087469853 @default.
• W3032544449 creator A5088390068 @default.
• W3032544449 date "2020-05-20" @default.
• W3032544449 modified "2023-10-17" @default.
• W3032544449 title "Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy." @default.
• W3032544449 doi "https://doi.org/10.1200/jco.2020.38.15_suppl.10005" @default.
• W3032544449 hasPublicationYear "2020" @default.
• W3032544449 type Work @default.
• W3032544449 sameAs 3032544449 @default.
• W3032544449 citedByCount "24" @default.
• W3032544449 countsByYear W30325444492020 @default.
• W3032544449 countsByYear W30325444492021 @default.
• W3032544449 countsByYear W30325444492022 @default.
• W3032544449 countsByYear W30325444492023 @default.
• W3032544449 crossrefType "journal-article" @default.
• W3032544449 hasAuthorship W3032544449A5003153310 @default.
• W3032544449 hasAuthorship W3032544449A5013399740 @default.
• W3032544449 hasAuthorship W3032544449A5022520811 @default.
• W3032544449 hasAuthorship W3032544449A5022668182 @default.
• W3032544449 hasAuthorship W3032544449A5025478490 @default.
• W3032544449 hasAuthorship W3032544449A5029398339 @default.
• W3032544449 hasAuthorship W3032544449A5036987287 @default.
• W3032544449 hasAuthorship W3032544449A5038759671 @default.
• W3032544449 hasAuthorship W3032544449A5040969461 @default.
• W3032544449 hasAuthorship W3032544449A5050031536 @default.
• W3032544449 hasAuthorship W3032544449A5052403208 @default.
• W3032544449 hasAuthorship W3032544449A5059961435 @default.
• W3032544449 hasAuthorship W3032544449A5064923908 @default.
• W3032544449 hasAuthorship W3032544449A5069983533 @default.
• W3032544449 hasAuthorship W3032544449A5070576000 @default.
• W3032544449 hasAuthorship W3032544449A5071144743 @default.
• W3032544449 hasAuthorship W3032544449A5082278497 @default.
• W3032544449 hasAuthorship W3032544449A5087156406 @default.
• W3032544449 hasAuthorship W3032544449A5087469853 @default.
• W3032544449 hasAuthorship W3032544449A5088390068 @default.
• W3032544449 hasConcept C121608353 @default.
• W3032544449 hasConcept C126322002 @default.
• W3032544449 hasConcept C143998085 @default.
• W3032544449 hasConcept C144301174 @default.
• W3032544449 hasConcept C2777701055 @default.
• W3032544449 hasConcept C2777863537 @default.
• W3032544449 hasConcept C2781433595 @default.
• W3032544449 hasConcept C38180746 @default.
• W3032544449 hasConcept C71924100 @default.
• W3032544449 hasConcept C90924648 @default.
• W3032544449 hasConceptScore W3032544449C121608353 @default.
• W3032544449 hasConceptScore W3032544449C126322002 @default.
• W3032544449 hasConceptScore W3032544449C143998085 @default.
• W3032544449 hasConceptScore W3032544449C144301174 @default.
• W3032544449 hasConceptScore W3032544449C2777701055 @default.
• W3032544449 hasConceptScore W3032544449C2777863537 @default.
• W3032544449 hasConceptScore W3032544449C2781433595 @default.
• W3032544449 hasConceptScore W3032544449C38180746 @default.
• W3032544449 hasConceptScore W3032544449C71924100 @default.
• W3032544449 hasConceptScore W3032544449C90924648 @default.
• W3032544449 hasIssue "15_suppl" @default.
• W3032544449 hasLocation W30325444491 @default.
• W3032544449 hasOpenAccess W3032544449 @default.
• W3032544449 hasPrimaryLocation W30325444491 @default.
• W3032544449 hasRelatedWork W2010130204 @default.
• W3032544449 hasRelatedWork W2361700749 @default.
• W3032544449 hasRelatedWork W2406617729 @default.
• W3032544449 hasRelatedWork W2780485172 @default.
• W3032544449 hasRelatedWork W2925460615 @default.
• W3032544449 hasRelatedWork W3030103226 @default.
• W3032544449 hasRelatedWork W3141065388 @default.
• W3032544449 hasRelatedWork W3157008565 @default.
• W3032544449 hasRelatedWork W3215105073 @default.
• W3032544449 hasRelatedWork W4200191628 @default.
• W3032544449 hasVolume "38" @default.
• W3032544449 isParatext "false" @default.
• W3032544449 isRetracted "false" @default.
• W3032544449 magId "3032544449" @default.
• W3032544449 workType "article" @default.